Transforming growth factor β activated kinase 1: A potential therapeutic target for rheumatic diseases

Rheumatology (United Kingdom)

Volumn 56, Issue 7, 2017, Pages 1060-1068

  Fechtner, Sabrina ^a   Fox, David A ^b   Ahmed, Salahuddin ^a  

^a WASHINGTON STATE UNIVERSITY   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Gout; Inflammation; Inhibition; Osteoarthritis; Rheumatoid arthritis; Sj gren's syndrome; TAK1

Indexed keywords

INTERLEUKIN 1BETA; PROTEIN SERINE THREONINE KINASE INHIBITOR; TOLL LIKE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1 INHIBITOR; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; ANTIRHEUMATIC AGENT; AUTACOID; CYTOKINE; INTERLEUKIN 6; MAP KINASE KINASE KINASE 7; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; TRANSFORMING GROWTH FACTOR BETA;

ENZYME INHIBITION; GOUT; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MOLECULAR PATHOLOGY; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; SJOEGREN SYNDROME; BLOOD; DRUG EFFECTS; FEMALE; MALE; METABOLISM; MOLECULARLY TARGETED THERAPY; PROGNOSIS; RHEUMATIC DISEASES;

ANTIRHEUMATIC AGENTS; CYTOKINES; FEMALE; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-1BETA; INTERLEUKIN-6; MALE; MAP KINASE KINASE KINASES; MOLECULAR TARGETED THERAPY; PROGNOSIS; RHEUMATIC DISEASES; TRANSFORMING GROWTH FACTOR BETA;

EID: 85021715613     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kew301     Document Type: Review

References (73)

1. Plotnikov A, Zehorai E, Procaccia S, Seger R. The MAPK cascades: Signaling components, nuclear roles and mechanisms of nuclear translocation. Biochim Biophys Acta 2011;1813:1619-33
2. Yamaguchi K, Shirakabe K, Shibuya H et al. Identification of a member of the MAPKKK family as a potential mediator of TGF-beta signal transduction. Science 1995;270:2008-11
3. Sato S, Sanjo H, Takeda K et al. Essential function for the kinase TAK1 in innate and adaptive immune responses. Nat Immunol 2005;6:1087-95
4. Shim JH, Xiao C, Paschal AE et al. TAK1, but not TAB1 or TAB2, plays an essential role in multiple signaling pathways in vivo. Genes Dev 2005;19:2668-81
5. Komatsu Y, Shibuya H, Takeda N et al. Targeted disruption of the Tab1 gene causes embryonic lethality and defects in cardiovascular and lung morphogenesis. Mech Dev 2002;119:239-49
6. Sanjo H, Takeda K, Tsujimura T et al. TAB2 is essential for prevention of apoptosis in fetal liver but not for interleukin-1 signaling. Mol Cell Biol 2003;23:1231-8
7. Courties G, Seiffart V, Presumey J et al. In vivo RNAimediated silencing of TAK1 decreases inflammatory Th1 and Th17 cells through targeting of myeloid cells. Blood 2010;116:3505-16
8. Schuman J, Chen Y, Podd A et al. A critical role of TAK1 in B-cell receptor-mediated nuclear factor kappaB activation. Blood 2009;113:4566-74
9. Wan YY, Chi H, Xie M, Schneider MD, Flavell RA. The kinase TAK1 integrates antigen and cytokine receptor signaling for T cell development, survival and function. Nat Immunol 2006;7:851-8
10. Sato S, Sanjo H, Tsujimura T et al. TAK1 is indispensable for development of T cells and prevention of colitis by the generation of regulatory T cells. Int Immunol 2006;18:1405-11
11. Rajasekaran K, Chu H, Kumar P et al. Transforming growth factor-beta-activated kinase 1 regulates natural killer cellmediated cytotoxicity and cytokine production. J Biol Chem 2011;286:31213-24
12. Narayanan KB, Park HH. Toll/interleukin-1 receptor (TIR) domain-mediated cellular signaling pathways. Apoptosis 2015;20:196-209
13. Ninomiya-Tsuji J, Kishimoto K, Hiyama A et al. The kinase TAK1 can activate the NIK-I kappaB as well as the MAP kinase cascade in the IL-1 signalling pathway. Nature 1999;398:252-6
14. Blonska M, Shambharkar PB, Kobayashi M et al. TAK1 is recruited to the tumor necrosis factor-alpha (TNF-alpha) receptor 1 complex in a receptor-interacting protein (RIP)-dependent manner and cooperates with MEKK3 leading to NF-kappaB activation. J Biol Chem 2005;280:43056-63
15. Adhikari A, Xu M, Chen ZJ. Ubiquitin-mediated activation of TAK1 and IKK. Oncogene 2007;26:3214-26
16. Wang C, Deng L, Hong M et al. TAK1 is a ubiquitindependent kinase of MKK and IKK. Nature 2001;412:346-51
17. Ogura N, Kondoh T. Molecular aspects in inflammatory events of temporomandibular joint: Microarray-based identification of mediators. Japanese Dental Sci Rev 2015;51:10-24
18. Besse A, Lamothe B, Campos AD et al. TAK1-dependent signaling requires functional interaction with TAB2/TAB3. J Biol Chem 2007;282:3918-28
19. Takaesu G, Kishida S, Hiyama A et al. TAB2, a novel adaptor protein, mediates activation of TAK1 MAPKKK by linking TAK1 to TRAF6 in the IL-1 signal transduction pathway. Mol Cell 2000;5:649-58
20. Kishimoto K, Matsumoto K, Ninomiya-Tsuji J. TAK1 mitogen-activated protein kinase kinase kinase is activated by autophosphorylation within its activation loop. J Biol Chem 2000;275:7359-64
21. Sakurai H, Miyoshi H, Mizukami J, Sugita T. Phosphorylation-dependent activation of TAK1 mitogen-activated protein kinase kinase kinase by TAB1. FEBS Lett 2000;474:141-5
22. Brown K, Vial SC, Dedi N et al. Structural basis for the interaction of TAK1 kinase with its activating protein TAB1. J Mol Biol 2005;354:1013-20
23. Ono K, Ohtomo T, Sato S et al. An evolutionarily conserved motif in the TAB1 C-terminal region is necessary for interaction with and activation of TAK1 MAPKKK. J Biol Chem 2001;276:24396-400
24. Zotti T, Vito P, Stilo R. The seventh ring: Exploring TRAF7 functions. J Cell Physiol 2012;227:1280-4
25. Petroski MD, Deshaies RJ. Function and regulation of cullin-RING ubiquitin ligases. Nat Rev Mol Cell Biol 2005;6:9-20
26. Hamidi A, von Bulow V, Hamidi R et al. Polyubiquitination of transforming growth factor beta (TGFbeta)-associated kinase 1 mediates nuclear factor-kappaB activation in response to different inflammatory stimuli. J Biol Chem 2012;287:123-33
27. Mao R, Fan Y, Mou Y et al. TAK1 lysine 158 is required for TGF-b-induced TRAF6-mediated Smad-independent IKK/NF-kB and JNK/AP-1 activation. Cell Signal 2011;23:222-7
28. Hildebrand JM, Yi Z, Buchta CM et al. Roles of tumor necrosis factor receptor associated factor 3 (TRAF3) and TRAF5 in immune cell functions. Immunol Rev 2011;244:55-74
29. Sakurai H, Suzuki S, Kawasaki N et al. Tumor necrosis factor-a-induced IKK phosphorylation of NF-kB p65 on Serine 536 is mediated through the TRAF2, TRAF5, and TAK1 signaling pathway. J Biol Chem 2003;278:36916-23
30. Lahiri M, Dixon WG. Risk of infection with biologic antirheumatic therapies in patients with rheumatoid arthritis. Best Pract Res Clin Rheumatol 2015;29:290-305
31. Meier FM, McInnes IB. Small-molecule therapeutics in rheumatoid arthritis: scientific rationale, efficacy and safety. Best Pract Res Clin Rheumatol 2014;28:605-24
32. Choi YS, Park JK, Kang EH et al. Cytokine signaling-1 suppressor is inducible by IL-1beta and inhibits the catabolic effects of IL-1beta in chondrocytes: its implication in the paradoxical joint-protective role of IL-1beta. Arthritis Res Ther 2013;15:R191
33. Hammaker DR, Boyle DL, Inoue T, Firestein GS. Regulation of the JNK pathway by TGF-beta activated kinase 1 in rheumatoid arthritis synoviocytes. Arthritis Res Ther 2007;9:R57
34. Geurts J, van den Brand BT, Wolf A et al. Toll-like receptor 4 signalling is specifically TGF-beta-activated kinase 1 independent in synovial fibroblasts. Rheumatology 2011;50:1216-25
35. Gottar-Guillier M, Dodeller F, Huesken D et al. The tyrosine kinase BMX is an essential mediator of inflammatory arthritis in a kinase-independent manner. J Immunol 2011;186:6014-23
36. Singh AK, Umar S, Riegsecker S, Chourasia M, Ahmed S. Regulation of TAK1 activation by epigallocatechin-3-gallate in RA synovial fibroblasts: Suppression of K63-linked autoubiquitination of TRAF6. Arthritis Rheumatol 2016;68:347-58
37. Jotanovic Z, Mihelic R, Sestan B, Dembic Z. Role of interleukin-1 inhibitors in osteoarthritis: an evidencebased review. Drugs Aging 2012;29:343-58
38. Burrage PS, Mix KS, BrinckerhoffCE. Matrix metalloproteinases: role in arthritis. Front Biosci 2006;11:529-43
39. Klatt AR, Klinger G, Neumüller O et al. TAK1 downregulation reduces IL-1b induced expression of MMP13, MMP1 and TNF-alpha. Biomed Pharmacother 2006;60:55-61
40. Ahmed S. Green tea polyphenol epigallocatechin 3-gallate in arthritis: progress and promise. Arthritis Res Ther 2010;12:208
41. Shim JH, Greenblatt MB, Xie M et al. TAK1 is an essential regulator of BMP signalling in cartilage. EMBO J 2009;28:2028-41
42. Gunnell LM, Jonason JH, Loiselle AE et al. TAK1 regulates cartilage and joint development via the MAPK and BMP signaling pathways. J Bone Miner Res 2010;25:1784-97
43. Klatt AR, Klinger G, Paul-Klausch B et al. TAK1 mediates the collagen-II-dependent induction of the COX-2 gene and PGE2 release in primary human chondrocytes. Connect Tissue Res 2010;51:452-8
44. Onodera Y, Teramura T, Takehara T, Shigi K, Fukuda K. Reactive oxygen species induce Cox-2 expression via TAK1 activation in synovial fibroblast cells. FEBS Open Bio 2015;5:492-501
45. Crofford LJ. COX-2 in synovial tissues. Osteoarthritis Cartilage 1999;7:406-8
46. Cronstein BN, Sunkureddi P. Mechanistic aspects of inflammation and clinical management of inflammation in acute gouty arthritis. Clin Rheumatol 2013;19:19-29
47. Khanna PP, FitzGerald J. Evolution of management of gout: a comparison of recent guidelines. Curr Opin Rheumatol 2015;27:139-46
48. Dinarello CA, Simon A, van der Meer JWM. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012;11:633-52
49. Bahia MS, Kaur M, Silakari P, Silakari O. Interleukin-1 receptor associated kinase inhibitors: potential therapeutic agents for inflammatory-and immune-related disorders. Cell Signal 2015;27:1039-55
50. Okada M, Matsuzawa A, Yoshimura A, Ichijo H. The lysosome rupture-activated TAK1-JNK pathway regulates NLRP3 inflammasome activation. J Biol Chem 2014;289:32926-36
51. Gong YN, Wang X, Wang J et al. Chemical probing reveals insights into the signaling mechanism of inflammasome activation. Cell Res 2010;20:1289-305
52. Sivera F, Wechalekar MD, Andres M, Buchbinder R, Carmona L. Interleukin-1 inhibitors for acute gout. Cochrane Database Syst Rev 2014;9:Cd009993
53. Sada PR, Isenberg D, Ciurtin C. Biologic treatment in Sjogren's syndrome. Rheumatology 2015;54:219-30
54. Yamada A, Arakaki R, Kudo Y, Ishimaru N. Targeting IL-1 in Sjögren's syndrome. Expert Opin Ther Targets 2013;17:393-401
55. Vijmasi T, Chen FY, Chen YT, Gallup M, McNamara N. Topical administration of interleukin-1 receptor antagonist as a therapy for aqueous-deficient dry eye in autoimmune disease. Mol Vis 2013;19:1957-65
56. Zilahi E, Tarr T, Papp G et al. Increased microRNA-146a/b, TRAF6 gene and decreased IRAK1 gene expressions in the peripheral mononuclear cells of patients with Sjören's syndrome. Immunol Lett 2012;141:165-8
57. Zoukhri D, Macari E, Choi SH, Kublin CL. c-Jun NH2-terminal kinase mediates interleukin-1beta-induced inhibition of lacrimal gland secretion. J Neurochem 2006;96:126-35
58. Sakurai H. Targeting of TAK1 in inflammatory disorders and cancer. Trends Pharmacol Sci 2012;33:522-30
59. Zippel N, Malik RA, Fromel T et al. Transforming growth factor-beta-activated kinase 1 regulates angiogenesis via AMP-activated protein kinase-alpha1 and redox balance in endothelial cells. Arterioscler Thromb Vasc Biol 2013;33:2792-9
60. Wu J, Powell F, Larsen NA et al. Mechanism and in vitro pharmacology of TAK1 inhibition by (5Z)-7-oxozeaenol. ACS Chem Biol 2012;8:643-50
61. Ninomiya-Tsuji J, Kajino T, Ono K et al. A resorcylic acid lactone, 5Z-7-oxozeaenol, prevents inflammation by inhibiting the catalytic activity of TAK1 MAPK kinase kinase. J Biol Chem 2003;278:18485-90
62. Zhou J, Zheng B, Ji J et al. LYTAK1, a novel TAK1 inhibitor, suppresses KRAS mutant colorectal cancer cell growth in vitro and in vivo. Tumour Biol 2015;36:3301-8
63. Melisi D, Xia Q, Paradiso G et al. Modulation of pancreatic cancer chemoresistance by inhibition of TAK1. J Natl Cancer Inst 2011;103:1190-204
64. Kilty I, Jones LH. TAK1 selective inhibition: state of the art and future opportunities. Future Med Chem 2015;7:23-33
65. Hornberger KR, Chen X, Crew AP et al. Discovery of 7-aminofuro[2, 3-c]pyridine inhibitors of TAK1: Optimization of kinase selectivity and pharmacokinetics. Bioorg Med Chem Lett 2013;23:4511-6
66. Petroski MD, Zhou X, Dong G et al. Substrate modification with lysine 63-linked ubiquitin chains through the UBC13-UEV1A ubiquitin-conjugating enzyme. J Biol Chem 2007;282:29936-45
67. Yu Y, Ge N, Xie M et al. Phosphorylation of Thr-178 and Thr-184 in the TAK1 T-loop is required for interleukin (IL)-1-mediated optimal NFkB and AP-1 activation as well as IL-6 gene expression. J Biol Chem 2008;283:24497-505
68. Shin M-S, Shinghirunnusorn P, Sugishima Y et al. Cross interference with TNF-a-induced TAK1 activation via EGFR-mediated p38 phosphorylation of TAK1-binding protein 1. Biochim Biophys Acta 2009;1793:1156-64
69. Kajino T, Ren H, Iemura S et al. Protein phosphatase 6 down-regulates TAK1 kinase activation in the IL-1 signaling pathway. J Biol Chem 2006;281:39891-6
70. Guo W, Wisniewski JA, Ji H. Hot spot-based design of small-molecule inhibitors for protein-protein interactions. Bioorg Med Chem Lett 2014;24:2546-54
71. Yin H, Lee G-i, Sedey KA et al. Terephthalamide derivatives as mimetics of helical peptides: disruption of the BclxL/Bak interaction. J Am Chem Soc 2005;127:5463-8
72. Tan L, Nomanbhoy T, Gurbani D et al. Discovery of type II inhibitors of TGF beta-activated kinase 1 (TAK1) and mitogen-activated protein kinase kinase kinase kinase 2 (MAP4K2). J Medicinal Chem 2015;58:183-96
73. Schiffelers RM, Ansari A, Xu J et al. Cancer siRNA therapy by tumor selective delivery with ligand-targeted sterically stabilized nanoparticle. Nucleic Acids Res 2004;32:e149